Neuphoria Therapeutics Inc. (NEUP) is a Nasdaq-listed clinical-stage biopharmaceutical company developing allosteric ion-channel modulators for central nervous system disorders. With a market capitalization of only about $15 million and a lead drug program that has been paused, the question of whether the shares can reach a $7 stock price target is best understood as a question about a pending merger rather than a purely fundamental one.
NEUP does not have enough credible, current analyst price targets to form a meaningful aggregate, so this article uses a fallback objective rather than an analyst consensus. The $7 figure is the last widely reported single-analyst target: H.C. Wainwright cut its target from $21 to $7 in December 2025, before analyst Joseph Pantginis downgraded the shares to Neutral from Buy in May 2026 and removed the target after the Phase 3 AFFIRM-1 trial of BNC210 for post-traumatic stress disorder (PTSD) did not support continued development. For context, Maxim Group last cited a $20 target in October 2025, while Lucid Capital reduced its target from $81 to $2.30 in October 2025 — the latter now sits below the current share price. None of these figures represents a current published consensus, and the $7 level should be read as a legacy benchmark rather than a maintained expectation.
Neuphoria last traded near $2.78, close to its 52-week low of $2.70 and well below its 52-week high of $5.53. Reaching $7 would require a gain of about 152%, which is a very large move for any equity and especially demanding for a company with roughly $1.17 million in trailing revenue and a net loss of about $13.45 million over the past year. The most plausible path toward such a level is not organic clinical execution — the BNC210 social-anxiety program was terminated and the PTSD program paused — but completion of the all-share merger with Scancell Holdings, under which the combined entity would operate as Scancell and list on Nasdaq under a new ticker. Shareholder value would then be governed by the exchange ratio and Scancell's own valuation rather than by Neuphoria's standalone pipeline.
The balance sheet is a genuine bright spot. Neuphoria reported roughly $19.87 million in cash against a market capitalization near $15 million, meaning the equity trades below its net cash position — a valuation floor that can support a stock even without near-term catalysts. Completion of the Scancell transaction, which was announced in July 2026 and is subject to shareholder and regulatory approvals, could reframe the value proposition entirely. A research collaboration with Merck & Co. on alpha7 receptor modulators also provides optionality, and any favorable merger or financing updates could spark outsized percentage moves in a thinly traded stock.
The principal obstacle is pipeline risk. With the BNC210 PTSD program paused and no active pivotal trials, Neuphoria lacks a clear clinical driver on a standalone basis, which is precisely why H.C. Wainwright downgraded the shares and withdrew its target. The pending Scancell merger could also fail to close, or its terms could value Neuphoria below the $7 benchmark once the exchange ratio is finalized. Micro-cap liquidity — average volume of only a few tens of thousands of shares — amplifies volatility, and investor sentiment in small-cap biotech has remained cautious following the trial setback.
The stock is trading below both its 50-day moving average near $3.48 and its 200-day moving average near $4.13, a bearish long-term structure. The 52-week low near $2.70 is the key support level; a break below it would open the door to fresh lows. On the upside, the 200-day average near $4.13 and the 52-week high of $5.53 represent the first meaningful resistance levels before any test of $7, which stands well above the recent trading range.
Analyst price targets typically reflect a research horizon of roughly 12 months, but for NEUP the more relevant timeline is the merger process itself, whose completion date has not been publicly fixed. Investors should watch the Scancell transaction's shareholder votes and regulatory approvals, any revised or newly published price targets, and Neuphoria's next earnings report, which was expected around mid-November 2026. Cash burn relative to the cash balance will also signal how much runway the standalone company has if the deal is delayed.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a low-liquidity, event-driven name like NEUP, these signals can help traders surface opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone.
Can NEUP reach $7? The target is a legacy, single-analyst figure rather than a live consensus, and it implies a very large move of roughly 152% from a price near $2.78. The strongest supports are a cash-rich balance sheet and the pending Scancell merger, while the primary obstacles are a paused pipeline and thin liquidity. The decisive variable is not earnings or clinical data but the merger's terms and completion. Investors should monitor deal approvals and any refreshed analyst coverage before drawing conclusions, and should treat the $7 level as a historical benchmark rather than a guaranteed outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NEUP has been loosely correlated with INBX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NEUP jumps, then INBX could also see price increases.
| Ticker / NAME | Correlation To NEUP | 1D Price Change % | ||
|---|---|---|---|---|
| NEUP | 100% | -2.54% | ||
| INBX - NEUP | 44% Loosely correlated | -1.23% | ||
| SLGL - NEUP | 36% Loosely correlated | -0.39% | ||
| COGT - NEUP | 35% Loosely correlated | -5.66% | ||
| ENSC - NEUP | 31% Poorly correlated | +3.24% | ||
| LKFT - NEUP | 30% Poorly correlated | -0.33% | ||
More | ||||